Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus ...

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...